10.06.25 -- You're In Charge Of Strategic Sourcing? What's That Actually Mean?

This webinar explores how next-generation cell line platforms streamline biologic development. Experts from Abzena, Revvity, and ProteoNic discuss flexible CLD strategies, integrated analytics, and technologies like AbZelectPRO™ and CHOSOURCE™ to boost productivity, achieve high-quality titers, reduce timelines, and de-risk scale-up, helping developers efficiently bring therapeutic antibodies and difficult-to-express proteins to the clinic. Click here to learn more.

Review the analytical considerations for subunit vaccines, vaccines that contain only the antigenic component(s) of a pathogen, and more specifically the assays needed.

Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based and biochemical assays, and more.

In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional; it is essential to survival and success.

Before an organization decides to acquire or in-license an asset for development, it's key to evaluate the chain of events and partners that progressed that asset to the point it is now at.

The moss Physcomitrium patens is especially good at producing glycoproteins. Established technology and prior knowledge are helping one company develop new therapies with it.

Delve into the complexities of scaling decisions and hear from biopharma developers and a CDMO on their mutual interest in achieving successful scale-up and strategies for avoiding common pitfalls.

Discover how transposon technology is being reimagined as a genetic engineering tool to create high-performing CHO cell lines for biotherapeutic production with better metabolic and glycan profiles.

Safeguard your cell banks with secure, compliant storage and streamlined delivery solutions that keep manufacturing on schedule and therapies moving forward.

High-quality process development aims to maintain a consistent process from toxicology through to GMP production runs, and can be aided by a capable, adaptable CDMO.

Examine five essential features of an effective CLD platform and how they can help address common development challenges in antibody and recombinant vaccine programs.

In a competitive environment, working with the right CDMO is vital for successful drug lifecycle management. We now serve more than half of the world’s leading biopharmaceutical companies.

Delivering high throughput capacity of the most challenging, high value drug products, Cytiva Supor™ Prime filters reduces product loss to waste, ensuring every drop counts towards maximizing yield.

Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.

Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.